-41%

est. 2Y upside i

HealthcareSeries B

Profluent is an AI-first protein design company. Founded in 2022, they develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine.

Rank

#599

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

Profluent presents a strong upside opportunity driven by its pioneering AI technology, robust proprietary data, and significant market potential in programmable biology.

Last updated: March 10, 2026

Bull (30%)+300%

Profluent's proprietary Protein Atlas and AI models drive rapid adoption of its protein design platform and OpenCRISPR-1, capturing 15% of the SAM ($255M revenue) within two years. This market leadership and innovation justify a 15x revenue multiple, pushing valuation to $3.8B, a 4x increase from the current valuation.

Base (45%)+75%

Profluent continues to grow steadily, expanding partnerships in therapeutics and agriculture. It captures 7% of the SAM ($119M revenue) within two years. A 14x revenue multiple leads to a $1.66B valuation, representing a 75% upside as the company solidifies its position in the AI-driven biology market.

Bear (25%)-60%

Regulatory hurdles and intense competition from well-funded AI drug discovery firms slow market penetration. Profluent captures only 2% of the SAM ($34M revenue) within two years. A lower 11x revenue multiple results in a $374M valuation, a 60% decrease from the current valuation, significantly impacting common stock value.

Est. time to liquidity~4.0 years

Preference Stack Risk

moderate

Investors hold $150M in liquidation preferences, representing approximately 15.8% of the current $950M valuation.

Dilution Risk

high

Given the 'very high' capital intensity and early stage (Series B), additional funding rounds are highly probable, leading to further dilution for common stock holders.

Secondary Liquidity

none

As a Series B company, there is currently no active secondary market or tender offers for employee equity.

Other — 9 roles

View all 9 open roles at Profluent →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Profluent's data — designed to show you've done your homework.

  • 1

    “Given the 'medium' incumbent threat and the rapid advancements in AI for biology, how does Profluent plan to maintain its strong competitive moat against large pharmaceutical companies and other well-funded AI drug discovery firms like Isomorphic Labs and Xaira Therapeutics?”

  • 2

    “With a composite TAM of $11.0B and ~0% market penetration for all vendors, what are the key milestones and commercialization strategies Profluent aims to achieve in the next 2-3 years to significantly capture market share in both drug discovery and agriculture/biomanufacturing?”

  • 3

    “Considering the Series B funding at a valuation approaching $1 billion and the 'very high' capital intensity, what is the company's anticipated timeline for future funding rounds and potential liquidity events for employees, and how does the preference stack impact common stock value in various exit scenarios?”

Community

Valuation Sentiment

Our model estimates -41% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.